C. Webers

发表

2021 EULAR points to consider to support people with rheumatic and musculoskeletal diseases to participate in healthy and sustainable paid work

A. Woolf, J. Hoving, A. Boonen, 2022, Annals of the Rheumatic Diseases.

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

R. Landewé, F. Pimentel-Santos, L. Gensler, 2022, Annals of the Rheumatic Diseases.

Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

R. Landewé, S. Ramiro, L. Falzon, 2022, Annals of the Rheumatic Diseases.

Impact of the COVID-19 pandemic on work productivity in patients with spondyloarthritis: results from the Dutch SpA-Net registry

A. Boonen, H. Vonkeman, A. V. van Tubergen, 2022, RMD open.

Construct Validity of Radiographs of the Feet to Assess Joint Damage in Patients with Gout

C. van Durme, A. Boonen, B. Spaetgens, 2017, The Journal of Rheumatology.

Patients with Gout Construct Validity of Radiographs of the Feet to Assess Joint Damage in and Annelies

B. Spaetgens, Boonen, T. Schoonbrood, 2016 .

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

R. Landewé, S. Ramiro, L. Falzon, 2022, Annals of the Rheumatic Diseases.

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial

M. Dougados, D. M. van der Heijde, A. Boonen, 2021, Annals of the Rheumatic Diseases.

Treat-to-target in axial spondyloarthritis: an observational study in daily practice

A. Boonen, P. T. ten Klooster, H. Vonkeman, 2021, Rheumatology.

Development, usability and acceptability of an integrated eHealth system for spondyloarthritis in the Netherlands (SpA-Net)

Y. van Eijk-Hustings, M. A. van de Laar, A. Boonen, 2019, RMD Open.

Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study.

M. Dougados, D. M. van der Heijde, R. Landewé, 2015, Rheumatology.

Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Braun et al

R. Landewé, S. Ramiro, X. Baraliakos, 2023, Annals of the Rheumatic Diseases.

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study

M. Dougados, D. M. van der Heijde, A. Boonen, 2018, RMD Open.

Non-pharmacological interventions to promote work participation in people with rheumatic and musculoskeletal diseases: a systematic review and meta-analysis from the EULAR taskforce on healthy and sustainable work participation

A. Woolf, A. Boonen, T. Stamm, 2023, RMD Open.

Economic Evaluations in Axial Spondyloarthritis

A. Boonen, C. Webers, 2019, Axial Spondyloarthritis.

Employment and the role of personal factors among patients with ankylosing spondylitis: a Dutch cross-sectional case-control study

M. A. van de Laar, D. M. van der Heijde, A. Boonen, 2018, RMD Open.

Go or no-go for treat-to-target in axial spondyloarthritis?

A. V. van Tubergen, C. Webers, M. Been, 2023, Current opinion in rheumatology.

Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands

W. Lems, A. Boonen, M. Nurmohamed, 2023, The Lancet. Rheumatology.

Depression in ankylosing spondylitis and the role of disease-related and contextual factors: a cross-sectional study

A. Boonen, S. Köhler, C. Leue, 2019, Arthritis Research & Therapy.

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL.

M. Dougados, A. Boonen, P. Claudepierre, 2020, Annals of the Rheumatic Diseases.

Validation and implementation of a patient-reported experience measure for patients with rheumatoid arthritis and spondyloarthritis in the Netherlands

A. Boonen, P. T. ten Klooster, H. Vonkeman, 2020, Clinical Rheumatology.

Performance of 3 Composite Measures for Disease Activity in Peripheral Spondyloarthritis

A. Boonen, P. T. ten Klooster, H. Vonkeman, 2021, The Journal of Rheumatology.

Costs of disease: The perspective matters

A. Boonen, B. Spaetgens, C. Webers, 2021, International journal of rheumatic diseases.

Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)

A. Boonen, R. Landewé, A. V. van Tubergen, 2020, Arthritis Research & Therapy.

Depression in ankylosing spondylitis and the role of disease-related and contextual factors: A structural equation modeling approach

A. Boonen, S. Köhler, C. Leue, 2019, Journal of Psychosomatic Research.

The value of correctly diagnosing axial spondyloarthritis for patients and society.

A. Boonen, M. Joore, S. Grimm, 2023, Seminars in arthritis and rheumatism.

The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?

A. Boonen, J. Braun, D. van der Heijde, 2022, Rheumatology.

Construct Validity of Radiographs of the Feet to Assess Joint Damage in Patients with Gout

C. van Durme, B. Spaetgens, T. Schoonbrood, 2017, The Journal of Rheumatology.

To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question.

P. Carron, Z. Lukasik, C. Webers, 2023, Best practice & research. Clinical rheumatology.